SciSparc Ltd Ordinary Shares SPRC 深 沪
交易中 08-12 10:15:33 美东时间
5.1457
-0.189
-3.55%
华盛通- 最 高5.38
- 今 开5.38
- 成交量 8176股
- 最 低 5.13
- 昨 收 5.335
- 总市值 5776.46万
- 52周最高 37.59
- 市盈率 静 --
- 换手率 0.07%
- 52周最低 4.137
- 委 比 -66.67%
- 总股本 1122.58万
- 历史最高 3865.68
- 量 比 5.14
- 振 幅 4.69%
- 历史最低 4.137
- 每 手 1
- 风险率 2.26%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Clearmind Medicine Publishes International Patent Application For Therapy Targeting Obesity And Metabolic Syndrome In Collaboration With SciSparc
Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major
08-07 19:39
SciSparc Announces Updates Regarding Proposed Merger; Form F-4 Registration Statement Has Been Declared Effective by SEC
SciSparc Ltd., a clinical-stage pharmaceutical company, has made progress toward its proposed merger with AutoMax Motors Ltd., Israel's leading electric vehicle importer. The merger, announced in April 2024, involves a reverse merger with SciSparc acquiring 100% of AutoMax's shares. Shareholder meetings to approve the merger will take place on August 25 and 28, 2025, with U.S. SEC approval already granted. SciSparc focuses on cannabinoid-based th...
07-30 20:34
SciSparc And Clearmind File International Patent For Novel Obesity And Liver Disease Treatment Combining MEAI and PEA
SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system,
07-30 20:13
SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease
SciSparc Ltd. and Clearmind Medicine Inc. have filed a new international patent application for their innovative combination therapy targeting obesity and MASLD. The therapy combines 5-methoxy-2-aminoindane and N-Acylethanolamines (MEAI) with Palmitoylethanolamide (PEA), leveraging its unique pharmacological properties. The collaboration aims to address significant global health challenges, with obesity affecting over 890 million people and NAFLD...
07-30 12:12
SciSparc Ltd. Executes Reverse Share Split Amid Financial Challenges
SciSparc Ltd. ( ($SPRC) ) has provided an announcement. On July 3, 2025, SciSpa...
07-23 04:27
SciSparc Ltd. Regains Nasdaq Compliance
SciSparc Ltd. ( ($SPRC) ) has provided an update. On July 22, 2025, SciSparc Lt...
07-22 20:57
SciSparc regains compliance with Nasdaq’s listing rule
SciSparc (NASDAQ:SPRC) has regained compliance with Nasdaq’s Listing Rule 5550(a)(2), which requires the company’s ordinary shares to maintain a minimum bid price of $1.00 per share. The Nasdaq staff ...
07-22 19:39
SciSparc Ltd. Regains Compliance with Nasdaq Minimum Bid Price Notification
SciSparc Ltd. (Nasdaq: SPRC), a clinical-stage pharmaceutical company focusing on cannabinoid-based therapies for central nervous system disorders, has regained compliance with Nasdaq Listing Rule 5550(a)(2) after its shares maintained a minimum bid price of $1.00 for 10 consecutive business days. The company develops treatments for Tourette Syndrome, Alzheimer's disease, autism, and epilepsy using THC and/or CBD. It also operates a hemp seed oil...
07-22 11:32
SciSparc to implement 1-for-21 reverse share split; shares down
SciSparc (NASDAQ:SPRC) will enact a 1-for-21 reverse share split of its ordinary shares. The reverse split will take effect at market open on July 3, 2025. SPRC shares fall 8.6% post-market on Tuesday...
06-25 05:16
SciSparc Announces 1-for-21 Reverse Share Split
SciSparc Ltd. (Nasdaq: SPRC) announced a 1-for-21 reverse share split effective July 3. Outstanding shares will decrease to approximately 534,600 from 11,225,751. Fractional shares will be rounded up, and ownership percentages remain unchanged. Trading resumes under "SPRC" with a new CUSIP number. No action needed for brokerage-held shares. SciSparc focuses on cannabinoid therapies for CNS disorders, including treatments for Tourette's, Alzheimer...
06-24 21:03
